Company registration number 10766569 (England and Wales)
VISITHEALTH LIMITED
ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 AUGUST 2025
VISITHEALTH LIMITED
COMPANY INFORMATION
Directors
I Galkin
Mr A Marey
D Yampolskiy
M Manko
Y Vasylieva
Company number
10766569
Registered office
1 Blythe Road
London
W140GH
Accountants
Chicksand Gordon Avis Limited
12 Northfields Prospect
Putney Bridge Road
London
SW18 1PE
VISITHEALTH LIMITED
CONTENTS
Page
Directors' report
1
Accountants' report
2
Profit and loss account
3
Balance sheet
4
Statement of changes in equity
5
Notes to the financial statements




Detailed profit and loss account
7 - 12




13-15
VISITHEALTH LIMITED
DIRECTORS' REPORT
FOR THE YEAR ENDED 31 AUGUST 2025
- 1 -

The directors present their annual report and financial statements for the year ended 31 August 2025.

Directors

The directors who held office during the year and up to the date of signature of the financial statements were as follows:

I Galkin
Mr A Marey
D Yampolskiy
M Manko
Y Vasylieva
Statement of directors' responsibilities

The directors are responsible for preparing the annual report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period.

In preparing these financial statements, the directors are required to:

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company’s transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Small companies exemption

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption.

On behalf of the board
I Galkin
Director
29 May 2026
VISITHEALTH LIMITED
ACCOUNTANTS' REPORT TO THE BOARD OF DIRECTORS ON THE PREPARATION OF THE UNAUDITED STATUTORY FINANCIAL STATEMENTS OF VISITHEALTH LIMITED FOR THE YEAR ENDED 31 AUGUST 2025
- 2 -

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Visithealth Limited for the year ended 31 August 2025 which comprise the profit and loss account, the balance sheet, the statement of changes in equity and the related notes from the company’s accounting records and from information and explanations you have given us.

 

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed at https://www.icaew.com/regulation.

Our work has been undertaken solely to prepare for your approval the financial statements of Visithealth Limited and state those matters that we have agreed to state to the board of directors of Visithealth Limited, as a body, in this report in accordance with ICAEW Technical Release 07/16 AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Visithealth Limited and its board of directors as a body, for our work or for this report.

It is your duty to ensure that Visithealth Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and loss of Visithealth Limited. You consider that Visithealth Limited is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the financial statements of Visithealth Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.

Chicksand Gordon Avis Limited
Chartered Accountants
12 Northfields Prospect
Putney Bridge Road
London
SW18 1PE
29 May 2026
VISITHEALTH LIMITED
PROFIT AND LOSS ACCOUNT
FOR THE YEAR ENDED 31 AUGUST 2025
- 3 -
2025
2024
Notes
£
£
Turnover
1,948,939
1,290,736
Cost of sales
(776,558)
(484,678)
Gross profit
1,172,381
806,058
Administrative expenses
(3,972,162)
(3,952,642)
Operating loss
(2,799,781)
(3,146,584)
Interest payable and similar expenses
(225,914)
(262,320)
Loss before taxation
(3,025,695)
(3,408,904)
Tax on loss
-
0
-
0
Loss for the financial year
(3,025,695)
(3,408,904)
VISITHEALTH LIMITED
BALANCE SHEET
AS AT
31 AUGUST 2025
31 August 2025
- 4 -
2025
2024
Notes
£
£
£
£
Fixed assets
Intangible assets
4
71,695
95,848
Tangible assets
5
3,280,837
3,394,650
3,352,532
3,490,498
Current assets
Debtors
6
635,475
531,555
Cash at bank and in hand
56,575
10,477
692,050
542,032
Creditors: amounts falling due within one year
7
(5,174,798)
(3,349,612)
Net current liabilities
(4,482,748)
(2,807,580)
Total assets less current liabilities
(1,130,216)
682,918
Creditors: amounts falling due after more than one year
8
(2,713,323)
(3,509,074)
Net liabilities
(3,843,539)
(2,826,156)
Capital and reserves
Called up share capital
9
1,545,971
1,294,932
Share premium account
6,323,014
4,565,741
Profit and loss reserves
(11,712,524)
(8,686,829)
Total equity
(3,843,539)
(2,826,156)

For the financial year ended 31 August 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the board of directors and authorised for issue on 29 May 2026 and are signed on its behalf by:
I Galkin
Director
Company registration number 10766569 (England and Wales)
VISITHEALTH LIMITED
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 AUGUST 2025
- 5 -
Share capital
Share premium account
Profit and loss reserves
Total
Notes
£
£
£
£
Balance at 1 September 2023
1,236,284
4,204,393
(5,277,925)
162,752
Year ended 31 August 2024:
Loss and total comprehensive income
-
-
(3,408,904)
(3,408,904)
Issue of share capital
9
58,648
361,348
-
419,996
Balance at 31 August 2024
1,294,932
4,565,741
(8,686,829)
(2,826,156)
Year ended 31 August 2025:
Loss and total comprehensive income
-
-
(3,025,695)
(3,025,695)
Issue of share capital
9
251,039
1,757,273
-
2,008,312
Balance at 31 August 2025
1,545,971
6,323,014
(11,712,524)
(3,843,539)
VISITHEALTH LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 AUGUST 2025
- 6 -
1
Accounting policies
Company information

Visithealth Limited is a private company limited by shares incorporated in England and Wales. The registered office is 1 Blythe Road, London, W140GH.

1.1
Basis of preparation

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

1.2
Going concern

Atruet the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3
Revenue

Revenue comprises sales of goods or services provided to customers net of value added tax and other sales taxes, less an appropriate deduction for actual and expected returns and discounts. Revenue is recognised when performance obligations are satisfied and the control of goods or services is transferred to the buyer. Where the performance obligation is satisfied over time, revenue is recognised in accordance with its progress towards complete satisfaction of that performance obligation.

 

When cash inflows are deferred and represent a financing arrangement, the promised consideration is adjusted for the effects of the time value of money, which is recognised as interest income.

The nature, timing of satisfaction of performance obligations and significant payment terms of the company's major sources of revenue are as follows:

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Revenue from contracts for the provision of professional services is recognised by reference to the stage of completion when the stage of completion, costs incurred and costs to complete can be estimated reliably. The stage of completion is calculated by comparing costs incurred, mainly in relation to contractual hourly staff rates and materials, as a proportion of total costs. Where the outcome cannot be estimated reliably, revenue is recognised only to the extent of the expenses recognised that are recoverable.

VISITHEALTH LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 AUGUST 2025
1
Accounting policies
(Continued)
- 7 -
1.4
Intangible fixed assets other than goodwill

Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

 

Intangible assets acquired on business combinations are recognised separately from goodwill at the acquisition date where it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity and the fair value of the asset can be measured reliably; the intangible asset arises from contractual or other legal rights; and the intangible asset is separable from the entity.

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Software
25% Reducing balance
Patents & licences
10% Straight line
1.5
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Freehold land and buildings
Not depreciated
Leasehold land and buildings
4% Straight line over the life of the lease
Plant and equipment
15% Reducing balance
Fixtures and fittings
25% Reducing balance
Computers
25% Reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.6
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

 

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

VISITHEALTH LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 AUGUST 2025
1
Accounting policies
(Continued)
- 8 -

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

1.7
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.8
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.9
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

VISITHEALTH LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 AUGUST 2025
1
Accounting policies
(Continued)
- 9 -
1.10
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.11
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.12
Leases
As lessee

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.

2
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
30
28
VISITHEALTH LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 AUGUST 2025
- 10 -
4
Intangible fixed assets
Software
Patents & licences
Total
£
£
£
Cost
At 1 September 2024 and 31 August 2025
324,234
2,684
326,918
Amortisation and impairment
At 1 September 2024
228,696
2,374
231,070
Amortisation charged for the year
23,885
268
24,153
At 31 August 2025
252,581
2,642
255,223
Carrying amount
At 31 August 2025
71,653
42
71,695
At 31 August 2024
95,538
310
95,848
5
Tangible fixed assets
Freehold land and buildings
Leasehold land and buildings
Plant and equipment
Fixtures and fittings
Computers
Total
£
£
£
£
£
£
Cost
At 1 September 2024
1,739,475
71,003
1,859,645
8,100
38,958
3,717,181
Additions
2,322
-
0
140,936
2,009
-
0
145,267
At 31 August 2025
1,741,797
71,003
2,000,581
10,109
38,958
3,862,448
Depreciation and impairment
At 1 September 2024
-
0
7,139
292,771
3,184
19,436
322,530
Depreciation charged in the year
-
0
2,840
249,276
1,522
4,693
258,331
Eliminated in respect of disposals
-
0
-
0
-
0
-
0
750
750
At 31 August 2025
-
0
9,979
542,047
4,706
24,879
581,611
Carrying amount
At 31 August 2025
1,741,797
61,024
1,458,534
5,403
14,079
3,280,837
At 31 August 2024
1,739,475
63,864
1,566,873
4,916
19,522
3,394,650
VISITHEALTH LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 AUGUST 2025
- 11 -
6
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
208,955
141,633
Other debtors
426,520
389,922
635,475
531,555
7
Creditors: amounts falling due within one year
2025
2024
£
£
Trade creditors
632,581
536,849
Taxation and social security
296,265
168,033
Other creditors
4,042,574
2,463,492
Accruals and deferred income
203,378
181,238
5,174,798
3,349,612
8
Creditors: amounts falling due after more than one year
2025
2024
£
£
Other loans
2,713,323
3,509,074
9
Called up share capital
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary shares of £1 each
1,545,971
1,294,932
1,545,971
1,294,932

On 19 December 2024, 251,039 Ordinary £1 shares were issued at a premium of £7 per share

10
Related party transactions
Transactions with related parties

During the year the company entered into the following transactions with related parties:

Included in Other creditors: Amounts falling due within one year - there is an amount of £1,406,032 (2024:£167,327) due to the directors of the company

Included in Creditors: Amounts falling due after one year - there is an amount of £2,713,323 (2024: £3,509,074) due to the directors of the company.

11
Controlling party
The company is controlled by the directors.
2025-08-312024-09-01falsefalsefalseCCH SoftwareCCH Accounts Production 2025.300No description of principal activityI GalkinMr A MareyD YampolskiyM MankoY Vasylieva107665692024-09-012025-08-3110766569bus:Director12024-09-012025-08-3110766569bus:Director22024-09-012025-08-3110766569bus:Director32024-09-012025-08-3110766569bus:Director42024-09-012025-08-3110766569bus:Director52024-09-012025-08-3110766569bus:RegisteredOffice2024-09-012025-08-31107665692025-08-31107665692023-09-012024-08-3110766569core:RetainedEarningsAccumulatedLosses2023-09-012024-08-3110766569core:RetainedEarningsAccumulatedLosses2024-09-012025-08-31107665692024-08-3110766569core:ComputerSoftware2025-08-3110766569core:PatentsTrademarksLicencesConcessionsSimilar2025-08-3110766569core:ComputerSoftware2024-08-3110766569core:PatentsTrademarksLicencesConcessionsSimilar2024-08-3110766569core:LandBuildingscore:OwnedOrFreeholdAssets2025-08-3110766569core:PlantMachinery2025-08-3110766569core:FurnitureFittings2025-08-3110766569core:ComputerEquipment2025-08-3110766569core:LandBuildingscore:OwnedOrFreeholdAssets2024-08-3110766569core:LandBuildings2024-08-3110766569core:PlantMachinery2024-08-3110766569core:FurnitureFittings2024-08-3110766569core:ComputerEquipment2024-08-3110766569core:CurrentFinancialInstrumentscore:WithinOneYear2025-08-3110766569core:CurrentFinancialInstrumentscore:WithinOneYear2024-08-3110766569core:CurrentFinancialInstruments2025-08-3110766569core:CurrentFinancialInstruments2024-08-3110766569core:Non-currentFinancialInstruments2025-08-3110766569core:Non-currentFinancialInstruments2024-08-3110766569core:ShareCapital2025-08-3110766569core:ShareCapital2024-08-3110766569core:SharePremium2025-08-3110766569core:SharePremium2024-08-3110766569core:RetainedEarningsAccumulatedLosses2025-08-3110766569core:RetainedEarningsAccumulatedLosses2024-08-3110766569core:ShareCapital2023-08-3110766569core:SharePremium2023-08-3110766569core:RetainedEarningsAccumulatedLosses2023-08-3110766569core:ShareCapitalOrdinaryShareClass12025-08-3110766569core:ShareCapitalOrdinaryShareClass12024-08-3110766569core:ShareCapital2023-09-012024-08-3110766569core:SharePremium2023-09-012024-08-3110766569core:ShareCapital2024-09-012025-08-3110766569core:SharePremium2024-09-012025-08-3110766569core:IntangibleAssetsOtherThanGoodwill2024-09-012025-08-3110766569core:ComputerSoftware2024-09-012025-08-3110766569core:PatentsTrademarksLicencesConcessionsSimilar2024-09-012025-08-3110766569core:LandBuildingscore:OwnedOrFreeholdAssets2024-09-012025-08-3110766569core:LandBuildingscore:LongLeaseholdAssets2024-09-012025-08-3110766569core:PlantMachinery2024-09-012025-08-3110766569core:FurnitureFittings2024-09-012025-08-3110766569core:ComputerEquipment2024-09-012025-08-3110766569core:ComputerSoftware2024-08-3110766569core:PatentsTrademarksLicencesConcessionsSimilar2024-08-31107665692024-08-3110766569core:LandBuildingscore:OwnedOrFreeholdAssets2024-08-3110766569core:LandBuildingscore:LeasedAssetsHeldAsLessee2024-08-3110766569core:PlantMachinery2024-08-3110766569core:FurnitureFittings2024-08-3110766569core:ComputerEquipment2024-08-3110766569core:LandBuildingscore:LeasedAssetsHeldAsLessee2025-08-3110766569core:LandBuildingscore:LeasedAssetsHeldAsLessee2024-09-012025-08-3110766569bus:OrdinaryShareClass12024-09-012025-08-3110766569bus:OrdinaryShareClass12025-08-3110766569bus:OrdinaryShareClass12024-08-3110766569bus:PrivateLimitedCompanyLtd2024-09-012025-08-3110766569bus:FRS1022024-09-012025-08-3110766569bus:AuditExemptWithAccountantsReport2024-09-012025-08-3110766569bus:FullAccounts2024-09-012025-08-31xbrli:purexbrli:sharesiso4217:GBP